Industry News

IndAS and why the numbers don't add up [Mint, New Delhi]
Kamada Ltd. announced today that it had attained positive results, meeting the primary endpoint, in a phase 2 trial of its Alpha-1 Antitrypsin Deficiency treatment. Following this announcement, Kamada's stock jumped 13%, and the company is traded at a market cap of NIS 680 million. The trial was carried out in the US, and is aimed at future registration of the product there."/>
Kamada succeeds in phase 2 inhaled drug trial [Globes, Tel Aviv, Israel]
Castlight Health, Inc., a leading health benefits platform provider, today announced that President and Chief Operating Officer John Doyle will present at the Morgan Stanley Global Healthcare Conference 2016 in New York, NY. Castlight Health's presentation is scheduled for Monday, September 12, 2016 at 12:30 p.m. Eastern Time and will be webcast live. An archive of the presentation will be available for a limited time and will be accessible at in the..."/>
Castlight Health to Present at the Morgan Stanley Global Healthcare Conference 2016
Centene Corporation announced today that its Pennsylvania subsidiary, Pennsylvania Health& Wellness, has been selected by the departments of Human Services and Aging to serve enrollees in the Community HealthChoices program statewide, pending regulatory approval and successful completion of readiness review. The five-year agreement, with an option to renew for two additional years, is expected to commence July 1, 2017, in the Southwest zone."/>
Centene's Pennsylvania Subsidiary Awarded Statewide Community HealthChoices Managed Care Agreement
Revance Therapeutics, Inc., a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the 2016 Wells Fargo Securities Healthcare Conference in Boston, MA. Revance management is scheduled to present on Wednesday, September 7 at 9:55am ET. Interested parties can access the live audio webcast for both of these conferences from the Investor Relations..."/>
Revance to Participate in the 2016 Wells Fargo Securities Healthcare Conference
Myriad Genetics, Inc. announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 2016 Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on September 12, 2016, at the Grand Hyatt New York in New York City.. The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’ s website at"/>
Myriad Genetics to Present at the 2016 Morgan Stanley Global Healthcare Conference
Relypsa, Inc., a biopharmaceutical company, today announced that the Phase 4 TOURMALINE study, which compared the efficacy and safety of Veltassa ® for oral suspension given with or without food for the treatment of hyperkalemia, met its primary endpoint. Results showed no statistically significant difference in the percent of patients achieving either week 3 or week 4 serum potassium in the target range between the group taking Veltassa with..."/>
Relypsa Announces Phase 4 Study Shows Veltassa® Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia
Prothena Corporation plc, a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in several upcoming investor conferences:. Credit Suisse Antibody Day on September 7, 2016 at 12:00 PM ET in New York, NY Citi’ s 11 th Annual Biotech Conference on September 8, 2016 in Boston, MA..."/>
Prothena to Participate in Upcoming September Investor Conferences
Veeva Systems Inc., a leading provider of industry cloud solutions for life sciences, today announced results for its fiscal second quarter ended July 31, 2016.."/>
Veeva Announces Fiscal 2017 Second Quarter Results
Atossa Genetics Inc. today announced that it intends to offer for sale shares of its common stock in an underwritten public offering. The company intends to use the net proceeds from this offering for working capital and to fund other general corporate purposes, including funding the costs of clinical trials. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or..."/>
Atossa Genetics Inc. Announces Proposed Public Offering of Common Stock
Sorrento Therapeutics, Inc., an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases, and other unmet medical needs, announced today that it will be presenting at two upcoming conferences in New York City. Sorrento will be presenting at the NewsMakers in the Biotech Industry Conference at 10:00 am on Friday, September 9 th, 2016 at the..."/>
Sorrento Therapeutics to Present at Two Upcoming Conferences in New York City
Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company, today announced that it has completed its public offering of 240,000 shares of Series B Convertible Preferred Stock and warrants to purchase 24,000,000 shares of common stock at a price to the public of $25.00 for a combination of one share of Series B Convertible Preferred Stock and 100 warrants to purchase one share of common stock each."/>
Provectus Biopharmaceuticals, Inc. Announces Closing of Public Offering
Pulse Biosciences, Inc.,, a medical technology company developing a proprietary therapeutic treatment platform based on Nano-Pulse Electro-Signaling, today announced that it has appointed Holly Hartman, Ph.D., J.D., as its Vice President, Business Development and Corporate Strategy. Hartman joins Pulse Biosciences after more than eight years in business development roles at Amgen where she helped to identify and evaluate strategic opportunities and..."/>
Pulse Biosciences Appoints Holly Hartman as Vice President of Business Development and Corporate Strategy
Vanda Pharmaceuticals Inc. today announced that the United States Patent and Trademark Office Patent Trials and Appeal Board declined the request by Roxane Laboratories, Inc. to institute an inter partes review of U.S. The' 432 patent was issued by the USPTO in September 2015 and expires in September 2025.. Vanda had previously announced on August 25, 2016 that Judge Gregory M. Sleet of the United States District Court for the District of..."/>
USPTO Dismisses Petition for Inter Partes Review of Fanapt® Patent
Henry Schein, Inc. has agreed to acquire an 80% ownership position in Poland-based dental distributor Marrodent, the company said. The transaction is subject to approval by Poland's competition authorities and is expected to close in 4 Q16. Financial terms were not disclosed."/>
Henry Schein to Acquire Polish Dental Products Distributor Marrodent
Cellceutix Corporation, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to announce today the addition of another senior executive to its management team. Jane Harness, MS, MP, has been appointed to the role of Vice President, Clinical Sciences and Portfolio Management. This new hire comes two months after pharmaceutical executive, Arthur..."/>
Cellceutix Further Expands Its Senior Management Team With the Addition of an Industry Veteran
Pediapharm Inc., a Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community, is pleased to announce it will be featured as a presenting company at the 18th Annual Rodman& Renshaw Global Investment Conference, sponsored by H.C."/>
Pediapharm Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
Quality Systems, Inc. announced today that its management will present at the Robert W. Baird 2016 Healthcare Conference in New York. Chief Financial Officer, Jamie Arnold, is scheduled to present on Wednesday, September 7, 2016, at 11:25 AM ET. A live audio-only webcast of the presentation and related presentation materials will be available on the investor relations section of the Company’ s website at"/>
Quality Systems, Inc. to Present at the Robert W. Baird 2016 Healthcare Conference
Centene Corp; and UPMC for You."/>
Pa. picks three firms to manage benefits for elderly and disabled []
Cigna CEO David M. Cordani to participate in the events Reinforces Cigna’ s commitment to reducing opioid misuse. BLOOMFIELD, Conn.---- Cigna continues its work to raise awareness of the country’ s opioid epidemic– and creating a path to improve treatment and prevention. It is sponsoring a two-city tour of NPR Generation Listen: America’ s Opioid Epidemic September 1 in Atlanta and September 19 in Chicago."/>
Cigna Sponsors ‘NPR Generation Listen’; Live Events Focus on the Opioid Epidemic
Agilent Technologies Inc. today introduced a new addition to its industry-leading line of gas chromatographs. The Agilent Intuvo 9000 GC solution offers users new innovative technology that will help laboratories meet operational, scientific and financial goals. Agilent Technologies unveils the new Intuvo 9000 GC System."/>
Agilent Technologies Introduces Transformational Technology for Gas Chromatography; New Intuitive GC Solution Improves User Experience
MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it will attend the Morgan Stanley Global Healthcare Conference in New York, NY. "Pete" Petit, Chairman and CEO, William C. Taylor,..."/>
MiMedx To Attend The Morgan Stanley Global Healthcare Conference

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary633 Articles
Information Technology575 Articles
Financials493 Articles
Industrials353 Articles
Health Care344 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at